Markets:

Overview

News

Currencies

International

Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

19.62 +1.12 (+6.05%)

Streaming Delayed Price Updated: 1:56 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Which stocks are experiencing notable movement on Thursday? ↗

July 10, 2025

Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

US Stocks Mixed; Initial Jobless Claims Fall ↗

July 10, 2025

Via Benzinga

Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Disease ↗

July 10, 2025

The study will continue onto a third and final analysis toward the end of the year.

Via Investor's Business Daily

Thursday's session: gap up and gap down stocks ↗

July 10, 2025

Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical ↗

May 28, 2025

Via Benzinga

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

Ultragenyx Pharmaceutical's Earnings: A Preview ↗

May 05, 2025

Via Benzinga

Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win ↗

July 10, 2025

Ultragenyx shares fall after Phase 3 study misses interim target, but analysts remain positive ahead of final OI data expected later this year.

Via Benzinga

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

July 10, 2025

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 10, 2025

Via Benzinga

Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

July 10, 2025

Via Benzinga

Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket ↗

July 10, 2025

Via Benzinga

Ultragenyx, Mereo Sink After Hours As Bone Drug Trial Continues Without Early Stop; Retail Traders Feel Selloff Is Overdone ↗

July 10, 2025

The companies now expect final data from the Orbit and Cosmic studies by the end of the year.

Via Stocktwits

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 09, 2025

Via Benzinga

What's going on in today's after hours session ↗

July 09, 2025

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

July 09, 2025

Data from Orbit and Cosmic studies expected around the end of the year

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

June 27, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 20, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Pharmaceutical Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

June 20, 2025

Via Benzinga

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

June 03, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 ↗

May 28, 2025

Ultragenyx sees rising revenue and analyst support as key drug launch approaches, with potential profitability projected for 2027.

Via Benzinga

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 20, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

May 14, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference

May 07, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

May 06, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

8 Health Care Stocks Whale Activity In Today's Session ↗

May 01, 2025

Via Benzinga

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

April 30, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 22, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning ↗

March 27, 2025

JP Morgan sees strong upside for Ultragenyx, citing setrusumab trial progress and pipeline growth, raising the price target to $117.

Via Benzinga

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 19, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.